Diagnosis and risk stratification of patients with cardiomyopathy

The DZHK biospecimen from patients with dilated or hypertrophic cardiomyopathy (DCM/HCM) enable the validation of common biomarkers from DCM/HCM patients in human iPSC-derived cardiomyocytes from patients with DCM/HCM mutations. These studies may support the development of future therapeutic and diagnostic approaches. A better understanding of the molecular mechanisms in cardiomyopathy via profiling of secreted biomarkers could facilitate future diagnostics and therapies for patients with cardiomyopathy.

Publications

There are no publications available yet.